Generate Biomedicines, Inc. (GENB)
D
Pipeline Grade
Financial Position (from SEC Filings)
$160.6M
Cash & Equivalents
$80.4M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$1,836M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-30 | Phase1 Readout | — |
| 2027-05-01 | Phase1 Readout | — |
| 2027-06-01 | Phase1 Readout | — |
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07359846 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | PHASE3 | Recruiting | 786 |
| NCT07276724 | A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | PHASE3 | Recruiting | 786 |
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | PHASE1 | Recruiting | 18 |
| NCT06920693 | Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants | PHASE1 | Active Not Recruiting | 40 |
| NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | PHASE1 | Recruiting | 37 |
| NCT07116889 | A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD | PHASE1 | Active Not Recruiting | 156 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.